{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:45:54Z","timestamp":1785890754947,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019213","name":"Amgen Australia Pty Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019213","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020537","name":"Merck Sharp & Dohme (Australia) Pty Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022896","name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102585","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:36:55Z","timestamp":1779899815000},"page":"102585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-8858","authenticated-orcid":false,"given":"Carole A.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danka S.","family":"Zebic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle F.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-3022","authenticated-orcid":false,"given":"David W.","family":"Pook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek J.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-3592","authenticated-orcid":false,"given":"Guy C.","family":"Toner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Vasey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Prithviraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-8724","authenticated-orcid":false,"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-8244","authenticated-orcid":false,"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-4352","authenticated-orcid":false,"given":"Craig","family":"Gedye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102585_bib0001","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102585_bib0002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102585_bib0003","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102585_bib0004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102585_bib0005","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102585_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2001-1326-3-13","article-title":"Granulocyte-to-dendritic cell-ratio as marker for the immune monitoring in patients with renal cell carcinoma","volume":"3","author":"Riemann","year":"2014","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.clgc.2026.102585_bib0007","first-page":"165","article-title":"Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells","volume":"27","author":"Porta","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2026.102585_bib0008","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7150\/jca.2.333","article-title":"Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?","volume":"2","author":"Porta","year":"2011","journal-title":"J Cancer"},{"key":"10.1016\/j.clgc.2026.102585_bib0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors \u2013 A systematic review","volume":"62","author":"De Groot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2026.102585_bib0010","first-page":"502.e15","article-title":"Receptor activator of NF-\u03bab (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma","volume":"36","author":"Steven","year":"2018","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.clgc.2026.102585_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010753","article-title":"RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells","volume":"13","author":"Pilard","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2026.102585_bib0012","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1200\/JCO.2023.41.16_suppl.9525","article-title":"CHARLI: a phase ib\/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma","volume":"41","author":"Lau","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102585_bib0013","doi-asserted-by":"crossref","first-page":"908436","DOI":"10.3389\/fimmu.2022.908436","article-title":"Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: a retrospective chart review","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2026.102585_bib0014","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s12094-018-02023-5","article-title":"The RANK\u2013RANKL axis: an opportunity for drug repurposing in cancer?","volume":"21","author":"Peters","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clgc.2026.102585_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1158\/2326-6066.CIR-23-0184","article-title":"Immune modulation with RANKL blockade through denosumab treatment in patients with cancer","volume":"12","author":"Chang","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clgc.2026.102585_bib0016","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03280667?term=pembrolizumab\/20denosumab\/20renal\/20cell\/20carcinoma&rank=1 . Accessed June 16, 2026."},{"key":"10.1016\/j.clgc.2026.102585_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clgc.2026.102585_bib0018","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial","volume":"126","author":"Motzer","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102585_bib0019","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2019.37.7_suppl.542","article-title":"Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): final analysis from the NIVOREN GETUG AFU 26 study","volume":"37","author":"Albiges","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102585_bib0020","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S1470-2045(23)00449-7","article-title":"Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial","volume":"24","author":"Grimm","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102585_bib0021","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.euf.2021.11.006","article-title":"Real-world data on the use of Nivolumab monotherapy in the treatment of advanced renal cell carcinoma after prior therapy: interim results from the noninterventional NORA study","volume":"8","author":"Grimm","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102585_bib0022","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102585_bib0023","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102585_bib0024","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/1078-0432.CCR-21-4115","article-title":"A randomized Phase II study of MEDI0680 in combination with Durvalumab versus Nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell carcinoma","volume":"28","author":"Voss","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102585_bib0025","doi-asserted-by":"crossref","first-page":"103602","DOI":"10.1016\/j.esmoop.2024.103602","article-title":"Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study","volume":"9","author":"Barth\u00e9l\u00e9my","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.clgc.2026.102585_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11809","article-title":"Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in Immune checkpoint inhibitor trials: a systematic review and meta-analysis","volume":"3","author":"Kok","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102585_bib0027","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102585_bib0028","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41571-018-0095-y","article-title":"Roles of the RANKL\u2013RANK axis in antitumour immunity \u2014 Implications for therapy","volume":"15","author":"Ahern","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102585_bib0029","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct Target Ther"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:43:54Z","timestamp":1785887034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000856"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102585","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102585"}}